SI20852B - Mezoprogestini (modulatorji receptorja progesterona) za zdravljenje in preprečevanje benignih hormonsko povzročenih ginekoloških motenj - Google Patents

Mezoprogestini (modulatorji receptorja progesterona) za zdravljenje in preprečevanje benignih hormonsko povzročenih ginekoloških motenj Download PDF

Info

Publication number
SI20852B
SI20852B SI200020042A SI200020042A SI20852B SI 20852 B SI20852 B SI 20852B SI 200020042 A SI200020042 A SI 200020042A SI 200020042 A SI200020042 A SI 200020042A SI 20852 B SI20852 B SI 20852B
Authority
SI
Slovenia
Prior art keywords
prevention
treatment
mesoprogestins
disorders
progesterone receptor
Prior art date
Application number
SI200020042A
Other languages
English (en)
Other versions
SI20852A (sl
Inventor
Kristof Chwalisz
Walter Elger
Gerd Schubert
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of SI20852A publication Critical patent/SI20852A/sl
Publication of SI20852B publication Critical patent/SI20852B/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Pričujoči izum opisuje uporabo mezoprogestinov, novega razreda modulatorjev receptorja progesterona (PRM) za zdravljenje in preprečevanje benignih hormonsko povzročenih ginekoloških motenj: a) za zdravljenje ginekoloških motenj, kot so endometrioza, maternični fibroidi, postoperativne peritonealne adhezije, disfunkcijska krvavitev (metroragija, menoragija) in dismenoreja; b) za preprečevanje ginekoloških motenj, kot so postoperativne, peritonealne adhezije, disfunkcijska krvavitev maternice (metroragija,menoragija) in dismenoreja; in c) postopek zdravljenja in preprečevanja zgoraj omenjenih motenj pri samici, prednostno ženski, ki potrebuje zdravljenje in preprečevanje ene ali več teh motenj z učinkovito količino mezoprogestina. Mezoprogestini so definirani kot spojine, ki imajo tako agonistične kot antagonistične aktivnosti na receptorju progesterona (PR) in vivo. Stabilizirajo funkcijo PR na intermediatni stopnji agonista in antagonista. Ustreznih funkcijskih stanj ne moremo doseči s progestini aliantiprogestini. Dnevni odmerek mezoprogestina je 0,5 do 100 mg, prednostno 5,0 do 50 mg in najbolj prednostno 10 do 25 mg. J867, J912, J956 in J1042 so prednostni mezoprogestini v smislu izuma.

Claims (3)

1/1 Sl 20852 Mezoprogestini za zdravljenje in preprečevanje benignih hormonsko povzročenih ginekoloških motenj Patentni zahtevki 1. Uporaba učinkovite količine mezoprogestina, izbranega iz skupine, ki jo sestavljajo J867, J912 in J956 za izdelavo zdravila za zdravljenje endometrioze, uterinih fibroidov, disfunkcijske krvavitve maternice (metroragija, menoragija) in dismenoreje, pri čemer je dnevni odmerek mezoprogestina 5,0 do 50 mg.
2. Uporaba učinkovite količine mezoprogestina, izbranega iz skupine, ki jo sestavljajo J867, J912 in J956 za izdelavo zdravila za preprečevanje disfunkcijske krvavitve maternice (metroragija, menoragija) in dismenoreje, pri čemer je dnevni odmerek mezoprogestina 5,0 do 50 mg.
3. Uporaba po zahtevku 1 ali 2, kjer je dnevni odmerek mezoprogestina 10 do 25 mg.
SI200020042A 1999-08-31 2000-08-31 Mezoprogestini (modulatorji receptorja progesterona) za zdravljenje in preprečevanje benignih hormonsko povzročenih ginekoloških motenj SI20852B (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38614199A 1999-08-31 1999-08-31
PCT/US2000/023770 WO2001015679A2 (en) 1999-08-31 2000-08-31 Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders

Publications (2)

Publication Number Publication Date
SI20852A SI20852A (sl) 2002-10-31
SI20852B true SI20852B (sl) 2009-06-30

Family

ID=23524338

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200020042A SI20852B (sl) 1999-08-31 2000-08-31 Mezoprogestini (modulatorji receptorja progesterona) za zdravljenje in preprečevanje benignih hormonsko povzročenih ginekoloških motenj

Country Status (34)

Country Link
EP (1) EP1229906B1 (sl)
JP (1) JP2003535029A (sl)
KR (3) KR20080066095A (sl)
AR (1) AR025457A1 (sl)
AT (1) ATE375160T1 (sl)
AU (1) AU781840B2 (sl)
BG (1) BG65817B1 (sl)
BR (1) BR0014161A (sl)
CA (1) CA2382580C (sl)
CO (1) CO5200772A1 (sl)
CZ (1) CZ2002704A3 (sl)
DE (1) DE60036723T2 (sl)
DK (1) DK1229906T3 (sl)
EA (1) EA007854B1 (sl)
EE (1) EE05172B1 (sl)
ES (1) ES2295050T3 (sl)
HR (1) HRP20020267A2 (sl)
HU (1) HUP0202429A3 (sl)
IL (1) IL148416A0 (sl)
LT (1) LT5034B (sl)
LV (1) LV12941B (sl)
ME (1) MEP13808A (sl)
MX (1) MXPA02002191A (sl)
NO (1) NO20020999L (sl)
NZ (1) NZ517471A (sl)
PE (1) PE20010578A1 (sl)
PL (1) PL198790B1 (sl)
PT (1) PT1229906E (sl)
RO (1) RO122179B1 (sl)
RS (1) RS50283B (sl)
SI (1) SI20852B (sl)
SK (1) SK287192B6 (sl)
UA (1) UA78184C2 (sl)
WO (1) WO2001015679A2 (sl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
ES2273061T3 (es) * 2002-08-02 2007-05-01 Schering Aktiengesellschaft Agentes moduladores de receptores de progesterona con actividad antigonadotropa elevada para el control de fertilidad femenina y para la terapia por reemplazo hormonal.
US20040097591A1 (en) * 2002-11-18 2004-05-20 Kristof Chwalisz Use of selective progesterone receptor modulators for the treatment of androgen deficiency
RU2301691C1 (ru) * 2005-12-20 2007-06-27 Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Российской академии медицинских наук Способ восстановительного лечения женщин репродуктивного возраста с тазовыми перитонеальными спайками с фиксированной или субфиксированной ретродевиацией матки
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
RU2339392C1 (ru) * 2007-05-21 2008-11-27 Федеральное Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Росмедтехнологий Способ остановки маточных кровотечений в пубертатном периоде
US9592213B2 (en) * 2009-06-17 2017-03-14 National University Corporation Kumamoto University Prophylactic and/or therapeutic agent for dysmenorrhea
US8399432B2 (en) * 2009-10-27 2013-03-19 Lipogen Ltd. Compositions and methods of treatment for alleviating premenstrual syndrome symptoms
CN114728013A (zh) * 2019-09-23 2022-07-08 斯坦福大学托管董事会 延长妊娠以及月经或妊娠的并发症的治疗方法
US12426782B2 (en) 2020-11-06 2025-09-30 The Board Of Trustees Of The Leland Stanford Junior University Systems and temporal alignment methods for evaluation of gestational age and time to delivery

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633244A1 (de) 1986-09-26 1988-03-31 Schering Ag Antigestagene zur hemmung der uterinen prostaglandinsynthese
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332284C2 (de) 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5576310A (en) * 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
EP1043325B1 (en) * 1994-12-22 2004-06-16 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5696130A (en) * 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Tricyclic steroid receptor modulator compounds and methods
WO1996023503A1 (de) 1995-02-02 1996-08-08 Schering Aktiengesellschaft Progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
AU710139B2 (en) * 1996-05-01 1999-09-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The 21-substituted progesterone derivatives as new antiprogestational agents
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
WO2000042031A2 (en) * 1999-01-14 2000-07-20 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
WO2000066590A2 (en) * 1999-05-04 2000-11-09 Ligand Pharmaceuticals, Inc. Tetracyclic progesterone receptor modulator compounds and methods

Also Published As

Publication number Publication date
SI20852A (sl) 2002-10-31
EP1229906B1 (en) 2007-10-10
KR20070058023A (ko) 2007-06-07
LT2002031A (en) 2003-02-25
ES2295050T3 (es) 2008-04-16
MXPA02002191A (es) 2002-09-30
KR20020027616A (ko) 2002-04-13
RS50283B (sr) 2009-09-08
PE20010578A1 (es) 2001-06-04
WO2001015679A3 (en) 2001-11-22
CA2382580C (en) 2009-05-19
DE60036723D1 (de) 2007-11-22
DK1229906T3 (da) 2008-02-11
LV12941B (en) 2003-06-20
IL148416A0 (en) 2002-09-12
MEP13808A (en) 2010-06-10
PL198790B1 (pl) 2008-07-31
HUP0202429A3 (en) 2004-04-28
AR025457A1 (es) 2002-11-27
YU14002A (sh) 2006-01-16
KR100864547B1 (ko) 2008-10-20
SK287192B6 (sk) 2010-02-08
CA2382580A1 (en) 2001-03-08
NO20020999D0 (no) 2002-02-28
AU781840B2 (en) 2005-06-16
AU6946600A (en) 2001-03-26
BR0014161A (pt) 2002-05-21
NZ517471A (en) 2004-02-27
WO2001015679A2 (en) 2001-03-08
SK2992002A3 (en) 2002-07-02
UA78184C2 (en) 2007-03-15
NO20020999L (no) 2002-03-14
HUP0202429A2 (en) 2002-10-28
EA200200282A1 (ru) 2002-10-31
BG106442A (bg) 2002-09-30
CO5200772A1 (es) 2002-09-27
LT5034B (lt) 2003-07-25
DE60036723T2 (de) 2008-07-17
ATE375160T1 (de) 2007-10-15
BG65817B1 (bg) 2010-01-29
JP2003535029A (ja) 2003-11-25
PT1229906E (pt) 2008-01-18
CZ2002704A3 (cs) 2003-02-12
EE05172B1 (et) 2009-06-15
HRP20020267A2 (en) 2004-04-30
PL353930A1 (en) 2003-12-15
EE200200104A (et) 2003-04-15
RO122179B1 (ro) 2009-02-27
KR100755109B1 (ko) 2007-09-04
KR20080066095A (ko) 2008-07-15
EP1229906A2 (en) 2002-08-14
EA007854B1 (ru) 2007-02-27

Similar Documents

Publication Publication Date Title
NO964155L (no) Progesteronantagonister for fremstilling av legemidler til behandling av dysfunksjonelle uterusblödninger
PT792152E (pt) Metodos de contracepcao
SI20852B (sl) Mezoprogestini (modulatorji receptorja progesterona) za zdravljenje in preprečevanje benignih hormonsko povzročenih ginekoloških motenj
AR011480A1 (es) ACIL-ANILIDAS SUSTITUIDAS CON RADICALES (HETERO) CICLICOS, NO ESTEROIDALES, CON ACTIVIDAD GESTÁGENA Y ANDRoGENA MIXTA.
YU69603A (sh) Atorvastatin kalcijum u farmaceutskom obliku, njegovoj smeši i farmaceutskoj formulaciji, koja sadrži atorvastatin kalcijum
WO2004103159A3 (en) Methods for modulating endometrium
WO2004000801A3 (en) Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions
ATE451123T1 (de) Vaginal verabreichbare zusammensetzung zur behandlung von uteriner dysrhythmie
WO2004000225A3 (en) Use of thio-oxindole derivatives in treatment of hormone-related conditions
BR0013009A (pt) Uso de antagonistas de cgrp e de inibidores de liberação de cgrp para combate a jatos quentes menopáusicos
YU13902A (sh) Mezoprogestini (progesteron receptor modulatori) kao komponente kontraceptivnih sredstava za žene
IL148739A0 (en) 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use
CL2003001544A1 (es) Compuestos derivados de 5-cicloalquenil-5h-cromeno[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, l
SI20851B (sl) Mezoprogestini (modulatorji receptorja progesterona) kot komponenta pripravkov za nadomestno zdravljenje s hormoni (NZH)
EA200702604A1 (ru) Производные бензофуранона как нестероидные модуляторы рецептора прогестерона
CL2003001545A1 (es) Compuestos derivados de 7,9-difluoro-5h-cromeno-[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, lei
WO2003035059A3 (en) Spermicides
WO2006042561A2 (en) Intrauterine contraceptive system with copper and progesterone
AR028470A1 (es) Ariltiofeno agonistas de vasopresina, el uso de los mismos para manufactura de un medicamento y composicion farmaceutica
Robb-Nicholson By the way, doctor. My doctor prescribed a low-dose vaginal estrogen cream, applied twice a week, for atrophic vaginitis. I've heard this dose is so low that it carries no health risk. Do you agree?
BR0010070A (pt) Uso de org 33245, kit contraceptivo, meio combinado para a dosagem de um progestogênio e um antiprogestogênio, e, métodos de contracepção, e de tratamento de sangramento uterino irregular ou de ruptura em uma fêmea utilizando uma preparação somente de progestogênio
WO2000032176A3 (en) Use of 17-ketosteroids for the treatment of toxoplasmosis and cryptosporidosis
Luukkainen THERAPEUTIC USE OF LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM, MIRENA
TH94755B (th) สารผสมทางเภสัชกรรมเพื่อการคุมกำเนิด และ สำหรับลดความเสี่ยงความผิดปกติที่เป็นมาแต่กำเนิด
WO2000059447A3 (fr) Utilisation d'hormones sexuelles pour l'obtention d'une composition pharmaceutique nasale utile pour le traitement des saignements uterins indesirables

Legal Events

Date Code Title Description
SP73 Change of data on owner

Owner name: SCHERING AKTIENGESELLSCHAFT; DE

Effective date: 20041118

IF Valid on the event date
OU02 Decision according to article 73(2) ipa 1992, publication of decision on partial fulfilment of the invention and change of patent claims

Effective date: 20090422

SP73 Change of data on owner

Owner name: BAYER SCHERING PHARMA AG; DE

Effective date: 20090325

KO00 Lapse of patent

Effective date: 20110413